Xenetic Biosciences, Inc. (NASDAQ:XBIO)

PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 7 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 8 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 8 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 8 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 8 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year 8 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform

Published on 07/31/2026 at 08:00, 1 hour 19 minutes ago

Caledonia Mining Corporation Plc Notification of Relevant Change to Significant Shareholder
Published on 07/31/2026 at 01:39, 7 hours 40 minutes ago

Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 9 hours 34 minutes ago

Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 10 hours 18 minutes ago

Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 10 hours 19 minutes ago

Eagle Plains Announces Approval of Warrant Expiry Extension

View all ACCESSWIRE

Published on 07/31/2026 at 09:00, 18 minutes ago

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
Published on 07/31/2026 at 09:00, 18 minutes ago

Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 07/31/2026 at 09:00, 18 minutes ago

Official List Notice
Published on 07/31/2026 at 09:00, 18 minutes ago

Adler strengthens its real estate portfolio
Published on 07/31/2026 at 09:00, 18 minutes ago

Baader Bank acquires stake in crypto provider Hyphe

View all EQS

Published on 07/31/2026 at 08:57, 21 minutes ago

FIRST-HALF 2026 RESULTS : Successful launch of the new strategic plan, activity maintained at the very high level of 2025 and solid results
Published on 07/31/2026 at 08:57, 21 minutes ago

RÉSULTATS SEMESTRIELS 2026 : Lancement réussi du nouveau plan stratégique, une activité maintenue au niveau très élevé de 2025 et des résultats solides
Published on 07/31/2026 at 08:32, 46 minutes ago

Abschluss der Übernahme der Scholz Recycling Gruppe
Published on 07/31/2026 at 08:32, 46 minutes ago

Completion of the acquisition of the Scholz Recycling Group
Published on 07/31/2026 at 08:32, 46 minutes ago

Réalisation de l’acquisition du groupe Scholz Recycling

View all LES ECHOS COMFI WIRE

News